US approves first dispersible tablet formulation of Tivicay
The formulation and an expanded indication for Tivicay tablets are currently under review in Europe
Read More
Tag: dolutegravir
ViiV submits dispersible form of dolutegravir in the US, EU
The company is seeking approval to market the formulation for children with HIV
Read More
GSK’s Dovato hits endpoints in late-stage study
In a Phase III study the drug combo was as effective in controlling HIV-1 as a Vemlidy combo.
Read More
ViiV secures EU nod for HIV therapy Dovato
Availability of the two-drug regimen is considered a significant development for people with the condition
Read More
GSK’s HIV drug Dovato gets FDA approval
It marks the first two-drug complete regimen for HIV-infected patients.
Read More
US filing for ViiV’s two-drug, single pill HIV treatment
ViiV Healthcare has submitted a New Drug Application to the US Food and Drug Administration seeking permission to market a single-tablet, two-drug regimen of dolutegravir and lamivudine for the treatment of HIV.
Read More
ViiV submits two-drug regimen for HIV in Europe
ViiV Healthcare has submitted an application in Europe for a single-tablet, two-drug regimen of dolutegravir (DTG) and lamivudine (3TC) for the treatment of HIV-1 infection.
Read More
ViiV unveils positive data for two-drug HIV regimens
ViiV Healthcare has unveiled positive clinical data for two two-drug HIV regimens ay the 22nd International AIDS conference in Amsterdam, showing long-term efficacy and non-inferiority to a current standard of care.
Read More
ViiV’s two-drug HIV regimen hits PhIII targets
ViiV Healthcare’s two-drug HIV regimen of Tivicay and Epivir has hit targets in late-stage trials, showing non-inferiority to a three-drug regimen and thus the potential to offer patients an alternative treatment strategy.
Read More
EU nod for ViiV/Janssen’s two-drug HIV regimen
ViiV Healthcare and Janssen have announced the approval of Juluca in Europe as the first two-drug regimen to treat some patients with HIV.
Read More
Six new therapies backed for EU approval
Six medicines have taken a big step towards European approval having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
ViiV kicks off PhIII trial of two-drug HIV regimen
ViiV Healthcare, an HIV specialist firm majority owned by GlaxoSmithKline, has announced the launch of a late-stage study investigating the effectiveness of a two-drug regimen programme in patients with HIV.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
